Infensa Biosciences

Infensa Bioscience develops a first-in-class therapeutic to protect heart and brain tissue during heart attacks and strokes. Its lead drug, IB409, works alongside standard care to reduce long-term injury and improve recovery, and has progressed from discovery through preclinical validation into Phase 1 human clinical trials based on world‑leading Australian research.